About this Research Topic
In the era of personalized medicine, preventing dyslipidemia involves a comprehensive approach that takes into account an individual's unique risk factors, genetic predisposition, and medical history. Dyslipidemia is a major modifiable risk factor for CVD. Personalized dyslipidemia refers to the individualized management and treatment of dyslipidemia.
The prevalence of dyslipidemia varies across populations and is influenced by risk factors such as age, gender, lifestyle, and genetic predisposition. Dyslipidemia is a condition characterized by abnormal levels of lipids (such as cholesterol and triglycerides) in the blood can be classified into hypercholesterolemia, hypertriglyceridemia, and mixed hyperlipidemia, characterized by elevated levels of either total cholesterol (TC) or triglycerides (TG), or a combined pattern. This condition is linked to an underlying genetic or an acquired cause. Medications for lipid disorders are chosen according to a person’s lipid levels and CVD risk.
Diagnostics and therapeutics for dyslipidaemic patients is a dynamic field with ongoing research and advancements. A variety of technologies is emerging to help clinicians provide patient-specific diagnosis and therapies. Personalized medicine is a clinical approach that has been subject of increasing interest in medical research in the last years, and is grounded in the idea that each individual clinical context is unique and manifests in particular ways that are driven by a specific clinical, physiological and molecular context, modulated by the exposure to environmental factors. The choice of lipid modifying treatment is largely based on the absolute level of cardiovascular risk and baseline lipid profile. Lowering serum lipids via PCSK9-targeting drugs reduce cholesterol levels in certain dyslipidaemic patients such as those with familial hypercholesterolemia. Researchers are investigating gene-editing techniques, such as CRISPR-Cas9, to modify genes related to lipid metabolism and potentially correct genetic dyslipidaemias. Nanoparticle-based drug delivery systems are being explored to enhance the targeted delivery of lipid-lowering medications, improving efficacy and reducing side effects. RNA-Based Therapeutics is an approach utilizing small interfering RNA (siRNA) to silence genes involved in dyslipidaemia, thus reducing the production of harmful lipids.
It is important to note that dyslipidemia is often asymptomatic, meaning individuals may not experience any noticeable symptoms. Regular screening and monitoring of lipid levels are crucial for early detection and appropriate management of dyslipidemia. Lifestyle modifications and medical interventions can effectively control dyslipidemia and reduce the associated risks.
The prevalence of dyslipidemia varies across populations and is influenced by risk factors such as age, gender, lifestyle, and genetic predisposition. Dyslipidemia is a condition characterized by abnormal levels of lipids (such as cholesterol and triglycerides) in the blood can be classified into hypercholesterolemia, hypertriglyceridemia, and mixed hyperlipidemia, characterized by elevated levels of either total cholesterol (TC) or triglycerides (TG), or a combined pattern. This condition is linked to an underlying genetic or an acquired cause. Medications for lipid disorders are chosen according to a person’s lipid levels and CVD risk.
Diagnostics and therapeutics for dyslipidaemic patients is a dynamic field with ongoing research and advancements. A variety of technologies is emerging to help clinicians provide patient-specific diagnosis and therapies. Personalized medicine is a clinical approach that has been subject of increasing interest in medical research in the last years, and is grounded in the idea that each individual clinical context is unique and manifests in particular ways that are driven by a specific clinical, physiological and molecular context, modulated by the exposure to environmental factors. The choice of lipid modifying treatment is largely based on the absolute level of cardiovascular risk and baseline lipid profile. Lowering serum lipids via PCSK9-targeting drugs reduce cholesterol levels in certain dyslipidaemic patients such as those with familial hypercholesterolemia. Researchers are investigating gene-editing techniques, such as CRISPR-Cas9, to modify genes related to lipid metabolism and potentially correct genetic dyslipidaemias. Nanoparticle-based drug delivery systems are being explored to enhance the targeted delivery of lipid-lowering medications, improving efficacy and reducing side effects. RNA-Based Therapeutics is an approach utilizing small interfering RNA (siRNA) to silence genes involved in dyslipidaemia, thus reducing the production of harmful lipids.
It is important to note that dyslipidemia is often asymptomatic, meaning individuals may not experience any noticeable symptoms. Regular screening and monitoring of lipid levels are crucial for early detection and appropriate management of dyslipidemia. Lifestyle modifications and medical interventions can effectively control dyslipidemia and reduce the associated risks.
Keywords: Personalized Medicine, Dyslipidemia, Prevention, Individualized, Lipid Levels, Epidemiology
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
